phase 3 clinical trial

Revolution Medicines has started shipping its experimental pancreatic cancer drug daraxonrasib to patients under an FDA-authorized early access program. The drug, not yet approved, showed in a Phase 3 trial that patients lived nearly twice as long as those receiving standard chemotherapy.

Eli Lilly's investigational obesity drug retatrutide met primary and key secondary endpoints in a phase 3 clinical trial, helping patients lose up to 30 percent of their body weight with a once-weekly injection. The highest dose achieved 28.3 percent weight loss, demonstrating clinically meaningful results.